RT Journal Article
SR Electronic
T1 Metabolomic profiling in small vessel disease identifies multiple associations with disease severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.13.21257190
DO 10.1101/2021.05.13.21257190
A1 Eric L. Harshfield
A1 Caroline J. Sands
A1 Anil M. Tuladhar
A1 Frank-Erik de Leeuw
A1 Matthew R. Lewis
A1 Hugh S. Markus
YR 2021
UL http://medrxiv.org/content/early/2021/05/14/2021.05.13.21257190.abstract
AB Cerebral small vessel disease (SVD) is a major cause of vascular cognitive impairment and dementia. There are few treatments, largely reflecting limited understanding of the underlying pathophysiology. Metabolomics can be used to identify novel risk factors in order to better understand pathogenesis and to predict disease progression and severity.We analysed data from 624 patients with symptomatic cerebral SVD from two prospective cohort studies. Serum samples were collected at baseline and patients underwent MRI scans and cognitive testing at regular intervals with up to 14 years of follow-up. Using ultra-performance liquid chromatography mass spectrometry and nuclear magnetic resonance spectroscopy, we obtained metabolic and lipidomic profiles from 369 annotated metabolites and 54,764 unannotated features and examined their association with respect to disease severity, assessed using MRI SVD markers, cognition, and future risk of all-cause dementia.Over 100 annotated metabolites were significantly associated with SVD imaging markers, cognition, and progression to dementia. Decreased levels of multiple glycerophospholipids, sphingolipids, and sterol lipids were associated with increased SVD load as evidenced by higher white matter hyperintensities (WMH) volume, lower mean diffusivity normalised peak height (MDNPH), greater brain atrophy, and impaired cognition. Higher levels of several amino acids and nucleotides were associated with higher WMH volume, greater atrophy, and lower MDNPH. Lower baseline levels of carnitines and creatinine were associated with higher annualised change in peak width of skeletonised mean diffusivity (PSMD), and several metabolites, including lower levels of valine, caffeine, and VLDL analytes, were associated with future dementia incidence. Additionally, we identified 1,362 unannotated features associated with lower MDNPH and 2,474 unannotated features associated with increased WMH volume.Our results show multiple distinct metabolic signatures that are associated with imaging markers of SVD, cognition, and conversion to dementia. Further research should assess causality and the use of metabolomic screening to improve the ability to predict future disease severity and dementia risk in SVD. The metabolomic profiles may also provide novel insights into disease pathogenesis and help identify novel treatment approaches.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the European Union's Horizon 2020 research and innovation programme under grant agreement No 667375 (CoSTREAM), and the Medical Research Council and National Institute for Health Research (NIHR) (grant MC PC 12025). This research was also supported by the Cambridge University Hospitals NIHR Biomedical Research Centre (BRC-1215-20014) and the NIHR Imperial Biomedical Research Centre. AMT is supported by the Dutch Heart Foundation (Hartstichting) (grant 2016 T044). HSM is supported by a NIHR Senior Investigator Award. Data collection in the SCANS cohort was funded by the Wellcome Trust. The views expressed in this publication are those of the authors and not necessarily those of the NIHR, NHS, or UK Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The SCANS study was approved by the Wandsworth (London) research ethics committee and all patients provided written informed consent. The SCANS study is registered with the UK Clinical Research Network (public.ukcrn.org.uk/; study ID 4577). The RUN-DMC study was approved by the Medical Review Ethics Committee region Arnhem- Nijmegen, and all participants signed an informed consent form.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw metabolomics data described in this study were generated at the Medical Research Council National Institute for Health Research (MRC-NIHR) National Phenome Centre. Derived data supporting the findings of this study are available from the corresponding author on request.ADLActivities of Daily LivingBI-LISABruker IVDr Lipoprotein Subclass AnalysisBI-QUANTBruker IVDr automated quantification of small molecule metabolitesDTIdiffusion tensor imagingDSMDiagnostic and Statistical Manual of Mental DisordersFDRfalse discovery rateLOESSlocally estimated scatterplot smoothingMDNPHmean diffusivity normalised histogram peak height measured within normal appearing white matter voxelsNMRnuclear magnetic resonanceUPLC-MSultra-performance liquid chromatography mass spectrometryPSMDpeak width of skeletonised mean diffusivityRUN-DMCRadboud University Nijmegen Diffusion Tensor and Magnetic Resonance Imaging CohortSCANSSt George’s Cognition and Neuroimaging in StrokeSDstandard deviationSVDsmall vessel diseaseWMHwhite matter hyperintensities